Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07346105 | Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies | available | — | — | Orca Biosystems, Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05738538 | Expanded Access to Ziftomenib | available | — | — | Kura Oncology, Inc.INDUSTRY | 0 | Jun 29, 2026 | clinicaltrials |
| Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS |
| available |
| — |
| — |
| Sellas Life Sciences GroupINDUSTRY |
| 0 |
| Apr 24, 2026 |
| clinicaltrials |
| NCT07215832 | Karyopharm Expanded Access Program for Selinexor(KEAP) | available | — | — | Karyopharm Therapeutics IncINDUSTRY | 0 | Mar 2, 2026 | clinicaltrials |
| NCT03123029 | Expanded Access to Venetoclax | available | — | — | AbbVieINDUSTRY | 0 | Jan 30, 2026 | clinicaltrials |
| NCT04745637 | Managed Access Programs for INC424, Ruxolitinib | available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 18, 2025 | clinicaltrials |
| NCT00854841 | The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder | available | — | — | Pusan National University HospitalOTHER | 0 | Mar 3, 2009 | clinicaltrials |
Data updated 4 days agoSource updated Sep 21, 2026source: clinicaltrials